The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gastrointestinal Stromal Tumor-Global Market Insights and Sales Trends 2024
Synopsis
Gastrointestinal stromal tumors (GISTs) start in special cells in the wall of the gastrointestinal (GI) tract, also known as the digestive tract.
The global Gastrointestinal Stromal Tumor market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gastrointestinal Stromal Tumor in various end use industries. The expanding demands from the Hospitals, Clinics, Specialized Cancer Treatment Centers and Other End Users, are propelling Gastrointestinal Stromal Tumor market. Stomach, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Small Intestine segment is estimated at % CAGR for the next seven-year period.
Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as pathologists. Until now, the role of radiotherapy in treatment of gastrointestinal stromal tumor remains decisively unestablished. For being inoperable, patients suffering from this malignant tumor opt for symptomatic treatments such as conventional chemotherapy.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastrointestinal Stromal Tumor, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastrointestinal Stromal Tumor market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastrointestinal Stromal Tumor market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastrointestinal Stromal Tumor sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastrointestinal Stromal Tumor covered in this report include Novartis, Sun Pharmaceutical, Pfizer, Bayer Aktiengesellschaft and NATCO Pharma, etc.
The global Gastrointestinal Stromal Tumor market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Sun Pharmaceutical
Pfizer
Bayer Aktiengesellschaft
NATCO Pharma
Global Gastrointestinal Stromal Tumor market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastrointestinal Stromal Tumor market, Segment by Type:
Stomach
Small Intestine
Others
Global Gastrointestinal Stromal Tumor market, by Application
Hospitals
Clinics
Specialized Cancer Treatment Centers
Other End Users
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastrointestinal Stromal Tumor companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Gastrointestinal stromal tumors (GISTs) start in special cells in the wall of the gastrointestinal (GI) tract, also known as the digestive tract.
The global Gastrointestinal Stromal Tumor market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gastrointestinal Stromal Tumor in various end use industries. The expanding demands from the Hospitals, Clinics, Specialized Cancer Treatment Centers and Other End Users, are propelling Gastrointestinal Stromal Tumor market. Stomach, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Small Intestine segment is estimated at % CAGR for the next seven-year period.
Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as pathologists. Until now, the role of radiotherapy in treatment of gastrointestinal stromal tumor remains decisively unestablished. For being inoperable, patients suffering from this malignant tumor opt for symptomatic treatments such as conventional chemotherapy.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastrointestinal Stromal Tumor, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastrointestinal Stromal Tumor market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastrointestinal Stromal Tumor market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastrointestinal Stromal Tumor sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastrointestinal Stromal Tumor covered in this report include Novartis, Sun Pharmaceutical, Pfizer, Bayer Aktiengesellschaft and NATCO Pharma, etc.
The global Gastrointestinal Stromal Tumor market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Sun Pharmaceutical
Pfizer
Bayer Aktiengesellschaft
NATCO Pharma
Global Gastrointestinal Stromal Tumor market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastrointestinal Stromal Tumor market, Segment by Type:
Stomach
Small Intestine
Others
Global Gastrointestinal Stromal Tumor market, by Application
Hospitals
Clinics
Specialized Cancer Treatment Centers
Other End Users
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastrointestinal Stromal Tumor companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gastrointestinal Stromal Tumor
1.1 Gastrointestinal Stromal Tumor Market Overview
1.1.1 Gastrointestinal Stromal Tumor Product Scope
1.1.2 Gastrointestinal Stromal Tumor Market Status and Outlook
1.2 Global Gastrointestinal Stromal Tumor Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gastrointestinal Stromal Tumor Market Size by Region (2018-2029)
1.4 Global Gastrointestinal Stromal Tumor Historic Market Size by Region (2018-2023)
1.5 Global Gastrointestinal Stromal Tumor Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gastrointestinal Stromal Tumor Market Size (2018-2029)
1.6.1 North America Gastrointestinal Stromal Tumor Market Size (2018-2029)
1.6.2 Europe Gastrointestinal Stromal Tumor Market Size (2018-2029)
1.6.3 Asia-Pacific Gastrointestinal Stromal Tumor Market Size (2018-2029)
1.6.4 Latin America Gastrointestinal Stromal Tumor Market Size (2018-2029)
1.6.5 Middle East & Africa Gastrointestinal Stromal Tumor Market Size (2018-2029)
2 Gastrointestinal Stromal Tumor Market by Type
2.1 Introduction
2.1.1 Stomach
2.1.2 Small Intestine
2.1.3 Others
2.2 Global Gastrointestinal Stromal Tumor Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gastrointestinal Stromal Tumor Historic Market Size by Type (2018-2023)
2.2.2 Global Gastrointestinal Stromal Tumor Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gastrointestinal Stromal Tumor Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gastrointestinal Stromal Tumor Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gastrointestinal Stromal Tumor Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gastrointestinal Stromal Tumor Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gastrointestinal Stromal Tumor Revenue Breakdown by Type (2018-2029)
3 Gastrointestinal Stromal Tumor Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Specialized Cancer Treatment Centers
3.1.4 Other End Users
3.2 Global Gastrointestinal Stromal Tumor Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gastrointestinal Stromal Tumor Historic Market Size by Application (2018-2023)
3.2.2 Global Gastrointestinal Stromal Tumor Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gastrointestinal Stromal Tumor Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gastrointestinal Stromal Tumor Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gastrointestinal Stromal Tumor Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gastrointestinal Stromal Tumor Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gastrointestinal Stromal Tumor Revenue Breakdown by Application (2018-2029)
4 Gastrointestinal Stromal Tumor Competition Analysis by Players
4.1 Global Gastrointestinal Stromal Tumor Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastrointestinal Stromal Tumor as of 2022)
4.3 Date of Key Players Enter into Gastrointestinal Stromal Tumor Market
4.4 Global Top Players Gastrointestinal Stromal Tumor Headquarters and Area Served
4.5 Key Players Gastrointestinal Stromal Tumor Product Solution and Service
4.6 Competitive Status
4.6.1 Gastrointestinal Stromal Tumor Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Gastrointestinal Stromal Tumor Products, Services and Solutions
5.1.4 Novartis Gastrointestinal Stromal Tumor Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Sun Pharmaceutical
5.2.1 Sun Pharmaceutical Profile
5.2.2 Sun Pharmaceutical Main Business
5.2.3 Sun Pharmaceutical Gastrointestinal Stromal Tumor Products, Services and Solutions
5.2.4 Sun Pharmaceutical Gastrointestinal Stromal Tumor Revenue (US$ Million) & (2018-2023)
5.2.5 Sun Pharmaceutical Recent Developments
5.3 Pfizer
5.3.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Gastrointestinal Stromal Tumor Products, Services and Solutions
5.3.4 Pfizer Gastrointestinal Stromal Tumor Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer Aktiengesellschaft Recent Developments
5.4 Bayer Aktiengesellschaft
5.4.1 Bayer Aktiengesellschaft Profile
5.4.2 Bayer Aktiengesellschaft Main Business
5.4.3 Bayer Aktiengesellschaft Gastrointestinal Stromal Tumor Products, Services and Solutions
5.4.4 Bayer Aktiengesellschaft Gastrointestinal Stromal Tumor Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer Aktiengesellschaft Recent Developments
5.5 NATCO Pharma
5.5.1 NATCO Pharma Profile
5.5.2 NATCO Pharma Main Business
5.5.3 NATCO Pharma Gastrointestinal Stromal Tumor Products, Services and Solutions
5.5.4 NATCO Pharma Gastrointestinal Stromal Tumor Revenue (US$ Million) & (2018-2023)
5.5.5 NATCO Pharma Recent Developments
6 North America
6.1 North America Gastrointestinal Stromal Tumor Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gastrointestinal Stromal Tumor Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Stromal Tumor Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gastrointestinal Stromal Tumor Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Stromal Tumor Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gastrointestinal Stromal Tumor Market Dynamics
11.1 Gastrointestinal Stromal Tumor Industry Trends
11.2 Gastrointestinal Stromal Tumor Market Drivers
11.3 Gastrointestinal Stromal Tumor Market Challenges
11.4 Gastrointestinal Stromal Tumor Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
